Project Grant K24AG098115
- The National Institute on Aging awarded the University of Pennsylvania $214,223 on March 5, 2026, under the Aging Research program (CFDA 93.866) to expand mentorship capacity and conduct patient-oriented research to improve care delivery for older adults. The award funds two primary aims. First, the recipient will build infrastructure to support an effective mentorship program for the next generation of research leaders conducting patient-oriented research on care delivery for older adults....
- The National Institute on Aging awarded The Johns Hopkins University $680,637 on September 15, 2026, under the Aging Research program (CFDA 93.866) to conduct a pragmatic clinical trial improving cognitive impairment screening in older adults with diabetes. The funded work develops and validates novel tools using natural language processing and large language models to identify cognitive impairment and Alzheimer's disease and related dementias screening events in electronic health records. The...
- The National Institute on Aging, part of the Department of Health and Human Services National Institutes of Health, awarded The Medical College of Wisconsin, Inc. $195,000 on June 1, 2026, under the Aging Research program (CFDA 93.866) to develop a voice-activated and touchscreen-controlled smart speaker intervention for adults aged 50 and older with poorly controlled type 2 diabetes. The research addresses the disproportionate diabetes burden among older adults, who experience nearly double the...
- The National Institute on Aging, National Institutes of Health, awarded the University of Pennsylvania $212,064 on July 1, 2026, under the Aging Research program (CFDA 93.866) to support Dr. Jordana Cohen's midcareer investigator award in patient-oriented research optimizing hypertension management in aging. The award funds protected time and support for Dr. Cohen to expand her mentoring program and patient-oriented research activities targeting the intersection of antihypertensive treatment...
- The National Institute on Aging awarded Weill Medical College of Cornell University $216,207 on July 15, 2026, under the Aging Research program (CFDA 93.866) to support a midcareer mentoring program on fragmented ambulatory care for people living with dementia. Dr. Lisa M. Kern, principal investigator and professor of medicine at Weill, leads development of a formal training program addressing fragmentation of care—the pattern wherein a patient's ambulatory care becomes so distributed across...
- The National Institute on Aging awarded the University of Maryland, College Park $568,481 on September 1, 2026, under the Aging Research program (CFDA 93.866) to advance research on early-life determinants, biosocial pathways, and dementia through the Network on Early-Life Determinants, Biosocial Pathways, and Dementia (EDDEM). The award funds multidisciplinary research collaborations that examine how early-life conditions shape dementia risk through social, behavioral, and biological...
- The National Institute on Aging awarded the University of Memphis $146,000 on September 4, 2026, under the Aging Research program (CFDA 93.866) to investigate longitudinal patterns of multiple behavioral risk factors and their joint effects on cognitive aging. The recipient will analyze 24 years of data from the Health and Retirement Study, a nationally representative longitudinal survey of U.S. adults age 51 and older, linked with neighborhood contextual data, to examine how physical...
- The National Institute on Aging awarded New York University $3.053 million on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct longitudinal research on caregiving networks and their consequences among adults ages 85 and older. The award funds the ARIC CARES study, embedded within the Atherosclerosis Risk in Communities Study cohort. The research will characterize care ecosystems and relational coordination (teamwork) among family caregivers, paid caregivers, and...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Johns Hopkins University $312,739 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to support a five-year mentored research scientist development award (K01). The award funds research to refine prediabetes definitions and improve diabetes prediction by integrating clinical factors, novel proteomic biomarkers, and polygenic risk scores. The specific...
- The National Institute on Aging awarded New York University $137,245 on July 15, 2026, under the Aging Research program (CFDA 93.866) to explore the relationship between obesity and dementia or Alzheimer's disease in older patients with end-stage kidney disease. The recipient will examine whether body mass index, augmented with novel anthropometric and body composition measures, associates with cognitive decline and dementia diagnosis in this population, and investigate whether intentional...
The National Institute on Aging awarded the University of Maryland, Baltimore $210,405 on September 15, 2026, under the Aging Research program (CFDA 93.866) to support mentorship in patient-oriented research improving health outcomes for older adults with type 2 diabetes. The award funds a Midcareer Investigator Award in Patient-Oriented Research (K24) with dual objectives: to provide Dr. McCoy with time and resources to mentor and support clinical investigators developing careers in patient-oriented research focused on older adults with type 2 diabetes, and to generate evidence on optimal type 2 diabetes treatment in older adults and on the distribution and health impacts of multilevel, multidimensional drivers of health in this heterogeneous population. The mentees will conduct impactful, distinct research investigations using a range of research methods within an interdisciplinary research team leveraging Dr. McCoy's research infrastructure. Research and mentoring activities will be conducted at the University of Maryland School of Medicine in Baltimore, Maryland. The period of performance runs from the award date through June 30, 2031. The award targets the growing population of older adults with type 2 diabetes—more than 16.5 million U.S. adults aged 65 and older—who experience potentially preventable disability, morbidity, and mortality despite advances in available pharmacotherapies. The project addresses the need for rigorous patient-oriented research on optimized pharmacotherapy selection, accessible high-quality care delivery, and mitigation of adverse social determinants of health in this population.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $210.4k | 9/2/26 |